149452-44-8

Basic information

• Product Name: (PIPERIDIN-4-YL)(4-TRIFLUOROMETHYLPHENYL)METHANONE
• Synonyms: (PIPERIDIN-4-YL)(4-TRIFLUOROMETHYLPHENYL)METHANONE;4-piperidinyl[4-(trifluoromethyl)phenyl]Methanone
• CAS NO: 149452-44-8
• Molecular Formula: C₁₃H₁₄F₃NO
• Molecular Weight: 257.254
• Mol File: 149452-44-8.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 334.0±42.0 °C(Predicted)
• Appearance: /
• Density: 1 +-.0.06 g/cm3(Predicted)
• PKA: 9?+-.0.10(Predicted)
• CAS DataBase Reference: (PIPERIDIN-4-YL)(4-TRIFLUOROMETHYLPHENYL)METHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: (PIPERIDIN-4-YL)(4-TRIFLUOROMETHYLPHENYL)METHANONE(149452-44-8)
• EPA Substance Registry System: (PIPERIDIN-4-YL)(4-TRIFLUOROMETHYLPHENYL)METHANONE(149452-44-8)

Safety Data

• Hazardous Substances Data: 149452-44-8(Hazardous Substances Data)

Usage

General Description

"(PIPERIDIN-4-YL)(4-TRIFLUOROMETHYLPHENYL)METHANONE" is a chemical compound with the molecular formula C16H16F3NO. It is a ketone derivative, with a piperidine ring and a trifluoromethylphenyl group attached to the carbon atom. (PIPERIDIN-4-YL)(4-TRIFLUOROMETHYLPHENYL)METHANONE is often used as an intermediate in organic synthesis, particularly in the production of pharmaceuticals and agrochemicals. It has properties that make it suitable for use in the synthesis of various compounds. However, it is important to handle this chemical with care, as it may have potential health hazards and should be used only by trained professionals following proper safety protocols.

Upstream product

• 402-43-7 p-trifluoromethylphenyl bromide 
• 213886-98-7 1-acetyl-N-methoxy-N-methylpiperidine-4-carboxamide 
• 402-51-7 4-(trifluoromethyl)phenylmagnesium bromide 
• 25503-91-7 N-acetyl-4-piperidinecarbonitrile 

Relevant articles and documents

Discovery of 4-benzoylpiperidine and 3-(piperidin-4-yl)benzo[d]isoxazole derivatives as potential and selective GlyT1 inhibitors

Regulation of glycine transporter 1 (GlyT1) activity is a currently investigated strategy in drug discovery for schizophrenia. This study developed a series of new 4-benzoylpiperidine derivatives as GlyT1 inhibitors by bioisosteric replacement and mimicking of the pyridine ring of RG1678. Among the 4-benzoylpiperidine derivatives, 23q showed an IC50 of 30 nM. Preliminary optimization of the blood-brain barrier penetration led to the discovery of 3-(piperidin-4-yl)benzo[d]isoxazole derivatives. Both series showed good selectivity over GlyT2, D1, D2, D3, 5-HT1A and 5-HT2A receptors. Moreover, behavioral testing showed 23q (40 mg kg-1, intragastric) can inhibit the hyperlocomotion induced by acute treatment of phencyclidine, and improve the impaired negative and cognitive symptoms in chronic phencyclidine-induced C57BL/6J mice. An interesting finding showed that 3-(piperidin-4-yl)benzo[d]isoxazole was a privileged scaffold of atypical antipsychotic agents but exhibited high selectivity and potency as a GlyT1 inhibitor.